Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials

Current Drug Targets

Volumn 13, Issue 12, 2012, Pages 1525-1534

  Ang, Joo Ern ^a,b   Kaye, Stan ^a,b   Banerji, Udai ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Clinical trials; Molecular targeted agents; Oncology; Pharmacodynamic biomarkers

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ABIRATERONE ACETATE; DACINOSTAT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; GEFITINIB; IMATINIB; INIPARIB; MAMMALIAN TARGET OF RAPAMYCIN; OLAPARIB; PLACEBO; PROTEIN KINASE B; TANESPIMYCIN; TRASTUZUMAB; VELIPARIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; CIRCULATING TUMOR CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HAIR FOLLICLE; HUMAN; IMMUNOFLUORESENCE; MASS SPECTROMETRY; METABOLOMICS; NEOPLASM; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRINCIPAL COMPONENT ANALYSIS; PROSTATE CANCER; PROTEOMICS; RECOMMENDED DRUG DOSE; REVIEW; SKIN BIOPSY; THROMBOCYTE RICH PLASMA; TISSUE TYPING; TRICHILEMMOMA; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BIOPSY; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; ENDPOINT DETERMINATION; GENOMICS; HUMANS; MICROARRAY ANALYSIS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEOMICS; RESEARCH DESIGN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84870184240     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530062     Document Type: Review

References (80)

1. Sawyers CL. The cancer biomarker problem. Nature 2008; 452(7187): 548-552.
2. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006; 2(12): 689-700.
3. Fricker J. Time for reform in the drug-development process. Lancet Oncol 2008; 9(12): 1125-1126.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3(8): 711-715.
5. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008; 13(1-2): 30-37.
6. Takimoto CH. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development. Eur J Cancer 2009; 45 Suppl 1: 436-438.
7. Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002; 38(16): 2189-2193.
8. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95.
9. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2(7): 566-580.
10. Hidalgo M, Messersmith W. Pharmacodynamic Studies in Drug Development. US: American Society of Clinical Oncology Educational Book 2004: 106-163.
11. Paez JG, Janne PA, Lee JC, et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 2004; 304(5676): 1497-1500.
12. Agulnik M, Oza AM, Pond GR, Siu LL. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 2006; 24(30): 4801-4807.
13. Banerji U, de Bono J, Judson I, Kaye S, Workman P. Biomarkers in early clinical trials: the committed and the skeptics. Clin Cancer Res 2008; 14(8): 2512; author reply 3-4.
14. Dowlati A, Haaga J, Remick SC, et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001; 7(10): 2971-2976.
15. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004; 10(19): 6661-6668.
16. Sarker D, Tan D, Brunetto A, et al. Safety and feasibility of serial tumour biopsies in phase I clinical trials: the Royal Marsden Hospital Drug Development Unit experience. National Cancer Research Institute Annual Conference 2009: C143.
17. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99(6):923-99.
18. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9(4): 302-312.
19. Lane H, Tanaka C, Kovarik J. Preclinical and clinical pharmacokinetic/pharmacy dynamic (PK/PD) modeling to help define an optimal biological dose for the oral mTOR inhibitor, RAD001, in oncology. J Clin Oncol 2003; 22(237): A951.
20. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26(10): 1588-1595.
21. Banerji U, Walton M, Raynaud F, et al. Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005; 11(19 Pt 1): 7023-7032.
22. Ramanathan RK, Egorin MJ, Eiseman JL, et al. Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers. Clin Cancer Res 2007; 13(6): 1769-1774.
23. d'Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cellengaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009; 33(3): 465-473.
24. Boulay A, Zumstein-Mecker S, Stephan C, et al. Anti tumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64(1): 252-261.
25. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000; 19(36): 4125-4133.
26. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17- demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23(18): 4152-4161.
27. de Bono JS, Kristeleit R, Tolcher A, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008; 14(20): 6663-6673.
28. Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 2008; 26: Abstr 3577.
29. Mahany JJ, Lewis N, Heath EI, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008; 26: Abstr 3579.
30. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364(3): 205-214.
31. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: Abstr 1007.
32. Ji J, Lee MP, Kadota M, et al. Pharmaco dynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201 Cancer Res 2011; 71(8S): Abstr 4527.
33. Camidge DR, Randall KR, Foster JR, et al. Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies. Br J Cancer 2005; 92(10): 1837-18341.
34. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3(7): 763-772.
35. Williams R, Baker AF, Ihle NT, Winkler AR, Kirkpatrick L, Powis G. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother Pharmacol 2006; 58(4): 444-450.
36. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123-134.
37. Albanell J, Rojo F, Averbuch S, et al. Pharmaco dynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20(1): 110-124.
38. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20(21): 4292-4302.
39. Hidalgo M, Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). Semin Oncol 2003; 30(3 Suppl 7): 25-33.
40. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9496): 1527-1537.
41. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-smallcell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22(5): 777-784.
42. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22(5): 785-794.
43. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23(11): 2493-2501.
44. Lievre A, Bachet J-B, Le Corre D, et al. KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. Cancer Res 2006; 66(8): 3992-395.
45. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26(10): 1603-1610.
46. Heaton S, Decordova S, Costigan S, et al. Building robust pharmacodynamic biomarker assays for phase I clinical trials. National Cancer Research Institute Annual Conference. 2009: Poster 231.
47. Sarker D, Kristeleit R, Mazina KE, et al. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC- 0941. J Clin Oncol 2009; 27(15S): A3538.
48. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009; 100(5): 671-675.
49. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90(12): 2317-2325.
50. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28): 4563-4571.
51. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95(3): 952-958.
52. Ergun S, Hohn HP, Kilic N, Singer BB, Tilki D. Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem Cell Rev 2008; 4(3): 169-177.
53. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow derived endothelial cells to human tumor vasculature. Nat Med 2005; 11(3): 261-262.
54. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelialcell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108(2): 452-459.
55. Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c- MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011; 29(10): 1271-1279.
56. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6(11): 835-845.
57. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452(7187): 571-579.
58. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007; 99(11): 838-846.
59. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1(2): 153-161.
60. Odunsi K, Wollman RM, Ambrosone CB, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005; 113(5): 782-788.
61. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancerprogression. Nature 2009; 457(7231): 910-914.
62. Serkova NJ, Niemann CU. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev Mol Diagn 2006; 6(5): 717-731.
63. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65(23): 10686-10691.
64. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103(1): 57-62.
65. O'Reilly KE, Rojo F, She QB, et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66(3): 1500-15108.
66. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(19): 3213-3221.
67. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351(8): 781-791.
68. Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009; 20(1): 27-33.
69. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450(7173): 1235-1239.
70. Tan SJ, Yobas L, Lee GY, Ong CN, Lim CT. Micro device for the isolation and enumeration of cancer cells from blood. Biomed Microdevices 2009; 11(4): 883-892.
71. Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009; 15(6): 2091-2097.
72. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102(45): 16368-16373.
73. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14(9): 985-990.
74. Bartella L, Thakur SB, Morris EA, et al. Enhancing non mass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007; 245(1): 80-87.
75. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology 1999; 213(2): 473-480.
76. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and threedimensional proton MR spectroscopic imaging. Radiology 1999; 213(2): 481-488.
77. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001; 22(4): 604-612.
78. Maxwell RJ, Martinez-Perez I, Cerdan S, et al. Pattern recognition analysis of 1H NMR spectra from perchloric acid extracts of human brain tumor biopsies. Magn Reson Med 1998; 39(6): 869-877.
79. Blankenberg FG, Katsikis PD, Storrs RW, et al. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 1997; 89(10): 3778-3786.
80. Chung YL, Troy H, Banerji U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003; 95(21): 1624-1633.